Rate My Professor Mohammed Rassool

Dr Mohammed Rassool is a researcher and Deputy Director at the Clinical HIV Research Unit (CHRU) at the University of the Witwatersrand. He holds an MBChB from MEDUNSA and conducts clinical research focused on the treatment and prevention of HIV, HIV co-infections, tuberculosis (including drug-susceptible, drug-resistant, and multidrug-resistant forms), and other opportunistic infections. He manages the TB portfolio at CHRU and serves as principal investigator or sub-investigator on multiple international collaborative protocols involving HIV, tuberculosis, and COVID-19. His work, conducted through partnerships with organizations including the NIH, EDCTP, Global TB Alliance, Médecins Sans Frontières, pharmaceutical companies, the TB Union, and USAID, has contributed to updates in South African Department of Health and World Health Organization treatment guidelines. Dr Rassool is a member of the NIH ACTG Network’s TB Transformation Scientific Group and has extensive experience in protocol implementation and clinical research site management, with additional interests in TB vaccine efficacy and HIV prevention.

He is affiliated with the University of the Witwatersrand and has co-authored peer-reviewed publications on topics such as all-oral regimens for rifampicin-resistant tuberculosis, remdesivir for COVID-19, nurse-led HIV care models, bedaquiline-containing regimens for tuberculosis, and host-directed therapies for pulmonary tuberculosis. These contributions appear in journals including the New England Journal of Medicine, The Lancet, and The Lancet Respiratory Medicine. Dr Rassool also participates in industry-funded HIV and COVID-19 research and supports efforts to inform global research priorities in infectious diseases.